Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 5/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26828253 | 0.92 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL16291661 | 0.86 | HPGD (0.62) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL17150677 | 0.86 | HPGD (0.62) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL27530648 | 0.86 | HPGD (0.66) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL2015039 | 0.86 | HPGD (0.66) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL26608596 | 0.86 | HPGD (0.66) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL16230337 | 0.85 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL25596826 | 0.84 | MEN1 (0.61) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL14627315 | 0.84 | MEN1 (0.61) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL28195249 | 0.84 | HPGD (0.68) | HPGDRECQLPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-11458149-B1 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220169580-A1 | METHODS OF CARBON-CARBON BOND FRAGMENTATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-02 | — | — | US | disclosed |
| CN-114502540-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3976192-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169580-A1 | METHODS OF CARBON-CARBON BOND FRAGMENTATION | CYCS, COX6C, COXFA4L2 | HPGD 2033/4885RECQL 4322/4885PTPN2 4568/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | HPGD 223/4885RECQL 977/4885PTPN2 1329/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | HPGD 223/4885RECQL 977/4885PTPN2 1329/4885 |
| US-11458149-B1 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | HPGD 223/4885RECQL 977/4885PTPN2 1329/4885 |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | HPGD 557/4885RECQL 821/4885PTPN2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.